יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Delcath Systems, Inc. (DCTH)

The price trajectory for Delcath Systems, Inc. (DCTH) shown below is based on the EV/EBITDA multiple, which currently stands at 0.00. The business relies on creating a closed interventional oncology ecosystem around the CHEMOSAT complex, requiring clinics to adhere to strict brand standards. The team is aggressively promoting the HEPZATO KIT and expanding the application of its developments, demonstrating persistence in commercialization and regulatory advancement.

The EV/EBITDA multiple compares the total enterprise value, including debt, with its operating profit before taxes, depreciation, and amortization. For Delcath Systems, Inc. (DCTH), which is developing liver chemotherapy systems, this metric reflects capitalization efficiency amid the diversification of oncology programs. The current value of 0.00 within the EV/EBITDA multiple trend helps determine the fair value of assets. This metric serves as a fundamental filter to separate market noise from the company's actual resilience.